Literature DB >> 22402607

SKLB1028, a novel oral multikinase inhibitor of EGFR, FLT3 and Abl, displays exceptional activity in models of FLT3-driven AML and considerable potency in models of CML harboring Abl mutants.

Z-X Cao, J-J Liu, R-L Zheng, J Yang, L Zhong, Y Xu, L-J Wang, C-H Zhang, B-L Wang, S Ma, Z-R Wang, H-Z Xie, Y-Q Wei, S-Y Yang.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 22402607     DOI： 10.1038/leu.2012.67

Source DB:  PubMed          Journal:  Leukemia        ISSN： 0887-6924            Impact factor:   11.528


× No keyword cloud information.
  4 in total

1.  Patients with FLT3-mutant AML needed to enroll on FLT3-targeted therapeutic clinical trials.

Authors:  Taylor Bucy; John M Zoscak; Motomi Mori; Uma Borate
Journal:  Blood Adv       Date:  2019-12-10

Review 2.  Small molecules in targeted cancer therapy: advances, challenges, and future perspectives.

Authors:  Lei Zhong; Yueshan Li; Liang Xiong; Wenjing Wang; Ming Wu; Ting Yuan; Wei Yang; Chenyu Tian; Zhuang Miao; Tianqi Wang; Shengyong Yang
Journal:  Signal Transduct Target Ther       Date:  2021-05-31

3.  Crotonoside exhibits selective post-inhibition effect in AML cells via inhibition of FLT3 and HDAC3/6.

Authors:  Yu-Zhi Li; Si Yu; Pei-Ao Yan; Dao-Yin Gong; Fang-Li Wu; Zhi He; Yu-Yao Yuan; An-Yan Zhao; Xue Tang; Ruo-Qi Zhang; Cheng Peng; Zhi-Xing Cao
Journal:  Oncotarget       Date:  2017-09-08

4.  Preclinical pharmacodynamic evaluation of a new Src/FOSL1 inhibitor, LY-1816, in pancreatic ductal adenocarcinoma.

Authors:  Wei Yang; Lingwei Meng; Kai Chen; Chenyu Tian; Bing Peng; Lei Zhong; Chunhui Zhang; Xin Yang; Jun Zou; Shengyong Yang; Linli Li
Journal:  Cancer Sci       Date:  2019-03-06       Impact factor: 6.716
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.